Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

biote Q3 2026 Results: Net Income $407K, Down 95.0% YoY

For the nine months ended September 30, 2026, biote Corp. reported a net loss of $4.2 million compared to a net income of $29.0 million in the prior year, driven by a decline in total revenue to $132.5 million and increased selling, general, and administrative expenses. The company's cash position decreased significantly to $8.9 million from $24.1 million at year-end 2025, while total stockholders' deficit widened to $57.6 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue43.348.0
Profit before tax1.48.5
Net income0.48.2
EPS (diluted, $ a share)$0.01$0.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-95.0%
Revenue, year on year-9.6%
Operating margin5.7%
Source

10-Q filed with the SEC, NASDAQ: BTMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

biote Corp.: key numbers

Share price
$0.9603Close, Nov 16
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from biote Corp.

All →
4:21 PM ET 8-K
Financial Results

biote Financial Results

biote Corp. reported third quarter 2026 revenue of $43.3 million, a 9.6% decrease year-over-year, primarily due to a decline in procedure revenue. The company maintained its full-year 2026 outlook, expecting revenue and Adjusted EBITDA to exceed $175 million and $25 million, respectively, despite slower-than-anticipated recovery in underlying demand.

Term
Q3 2026

“While a recent improvement in procedure volume provides early evidence of stabilization in underlying demand, our return to growth is progressing more slowly than anticipated. Our immediate priorities are to improve sales productivity and strengthen engagement with our trained practitioners as we work toward a return to revenue growth.”

Bob Peterson, Biote’s interim Chief Executive Officer

“Our strategic initiatives remain central to strengthening the business, and the foundational work completed over the past year provides a basis for improvement. As we move forward, we remain focused on enhancing the practitioner experience, increasing sales productivity, and supporting a return to growth.”

Bob Peterson, Biote’s interim Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.